Friedegund Meier
Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
Wagner N, Lenders M, Kühl K, Reinhardt L, Fuchß M, Ring N, Stäger R, Zellweger C, Ebel C, Kimeswenger S, Oellinger A, Amaral T, Forschner A, Leiter U, Klumpp B, Hoetzenecker W, Terheyden P, Mangana J, Loquai C, Cozzio A, Garbe C, Meier F, Eigentler T, Flatz L. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy. Eur J Cancer 2023; 196:113425.
Nov 21, 2023Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
Nov 21, 2023Eur J Cancer 2023; 196:113425
Wagner Nikolaus, Lenders Max M, Kühl Kathrin, Reinhardt Lydia, Fuchß Milena, Ring Natalie, Stäger Ramon, Zellweger Caroline, Ebel Chiara, Kimeswenger Susanne, Oellinger Angela, Amaral Teresa, Forschner Andrea, Leiter Ulrike, Klumpp Bernhard, Hoetzenecker Wolfram, Terheyden Patrick, Mangana Joanna, Loquai Carmen, Cozzio Antonio, Garbe Claus, Meier Friedegund, Eigentler Thomas Kurt, Flatz Lukas
Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases.
Chatziioannou E, Roßner J, Aung T, Rimm D, Niessner H, Keim U, Serna-Higuita L, Bonzheim I, Kuhn Cuellar L, Westphal D, Steininger J, Meier F, Pop O, Forchhammer S, Flatz L, Eigentler T, Garbe C, Röcken M, Amaral T, Sinnberg T. Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases. EBioMedicine 2023; 93:104644.
Jun 7, 2023Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases.
Jun 7, 2023EBioMedicine 2023; 93:104644
Chatziioannou Eftychia, Roßner Jana, Aung Thazin New, Rimm David L, Niessner Heike, Keim Ulrike, Serna-Higuita Lina María, Bonzheim Irina, Kuhn Cuellar Luis, Westphal Dana, Steininger Julian, Meier Friedegund, Pop Oltin Tiberiu, Forchhammer Stephan, Flatz Lukas, Eigentler Thomas Kurt, Garbe Claus, Röcken Martin, Amaral Teresa, Sinnberg Tobias
Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma.
Gaissler A, Bochem J, Spreuer J, Ottmann S, Martens A, Amaral T, Wagner N, Claassen M, Meier F, Terheyden P, Garbe C, Eigentler T, Weide B, Pawelec G, Wistuba-Hamprecht K. Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma. J Immunother Cancer 2023; 11
Jun 1, 2023Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma.
Jun 1, 2023J Immunother Cancer 2023; 11
Gaissler Andrea, Bochem Jonas, Spreuer Janine, Ottmann Shannon, Martens Alexander, Amaral Teresa, Wagner Nikolaus, Claassen Manfred, Meier Friedegund, Terheyden Patrick, Garbe Claus, Eigentler Thomas Kurt, Weide Benjamin, Pawelec Graham, Wistuba-Hamprecht Kilian
Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis.
Müller-Jensen L, Zierold S, Versluis J, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, Blank C, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel J, Ugurel S, Zimmer L, Banks P, Spain L, Soon J, Enokida T, Tahara M, Kähler K, Seggewiss-Bernhardt R, Harvey C, Long G, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French L, Knauss S, Heinzerling L. Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis. Data Brief 2022; 45:108649.
Sep 30, 2022Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis.
Sep 30, 2022Data Brief 2022; 45:108649
Müller-Jensen Leonie, Zierold Sarah, Versluis Judith M, Boehmerle Wolfgang, Huehnchen Petra, Endres Matthias, Mohr Raphael, Compter Annette, Blank Christian U, Hagenacker Tim, Meier Friedegund, Reinhardt Lydia, Gesierich Anja, Salzmann Martin, Hassel Jessica C, Ugurel Selma, Zimmer Lisa, Banks Patricia, Spain Lavinia, Soon Jennifer A, Enokida Tomohiro, Tahara Makoto, Kähler Katharina C, Seggewiss-Bernhardt Ruth, Harvey Catriona, Long Georgina V, Schöberl Florian, von Baumgarten Louisa, Hundsberger Thomas, Schlaak Max, French Lars E, Knauss Samuel, Heinzerling Lucie M
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.
Müller-Jensen L, Zierold S, Versluis J, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, Blank C, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel J, Ugurel S, Zimmer L, Banks P, Spain L, Soon J, Enokida T, Tahara M, Kähler K, Seggewiss-Bernhardt R, Harvey C, Long G, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French L, Knauss S, Heinzerling L. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study. Eur J Cancer 2022; 175:224-235.
Sep 22, 2022Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.
Sep 22, 2022Eur J Cancer 2022; 175:224-235
Müller-Jensen Leonie, Zierold Sarah, Versluis Judith M, Boehmerle Wolfgang, Huehnchen Petra, Endres Matthias, Mohr Raphael, Compter Annette, Blank Christian U, Hagenacker Tim, Meier Friedegund, Reinhardt Lydia, Gesierich Anja, Salzmann Martin, Hassel Jessica C, Ugurel Selma, Zimmer Lisa, Banks Patricia, Spain Lavinia, Soon Jennifer A, Enokida Tomohiro, Tahara Makoto, Kähler Katharina C, Seggewiss-Bernhardt Ruth, Harvey Catriona, Long Georgina V, Schöberl Florian, von Baumgarten Louisa, Hundsberger Thomas, Schlaak Max, French Lars E, Knauss Samuel, Heinzerling Lucie M
Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade.
Gaissler A, Meldgaard T, Heeke C, Babaei S, Tvingsholm S, Bochem J, Spreuer J, Amaral T, Wagner N, Klein R, Meier F, Garbe C, Eigentler T, Pawelec G, Claassen M, Weide B, Hadrup S, Wistuba-Hamprecht K. Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade. Front Immunol 2022; 13:906352.
Jul 7, 2022Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade.
Jul 7, 2022Front Immunol 2022; 13:906352
Gaissler Andrea, Meldgaard Trine Sundebo, Heeke Christina, Babaei Sepideh, Tvingsholm Siri Amanda, Bochem Jonas, Spreuer Janine, Amaral Teresa, Wagner Nikolaus, Klein Reinhild, Meier Friedegund, Garbe Claus, Eigentler Thomas K, Pawelec Graham, Claassen Manfred, Weide Benjamin, Hadrup Sine Reker, Wistuba-Hamprecht Kilian
Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study
Wagner N, Schraag A, Klumpp B, Hoetzenecker W, Berking C, Richtig E, Ziemer M, Mangana J, Terheyden P, Loquai C, Nguyen V, Gebhardt C, Meier F, Diem S, Cozzio A, Flatz L, Röcken M, Garbe C, Gassenmaier M, Weide B, Leiter U, Lenders M, Kühl K, Reinhardt L, André F, Dudda M, Ring N, Ebel C, Stäger R, Zellweger C, Lang R, Paar M, Gussek P, Richtig G, Stürmer S, Kimeswenger S, Oellinger A, Forschner A, Eigentler T. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. J Immunother Cancer 2021; 9
Jan 1, 2021Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study
Jan 1, 2021J Immunother Cancer 2021; 9
Wagner Nikolaus, Schraag Amadeus, Klumpp Bernhard, Hoetzenecker Wolfram, Berking Carola, Richtig Erika, Ziemer Mirjana, Mangana Johanna, Terheyden Patrick, Loquai Carmen, Nguyen Van Anh, Gebhardt Christoffer, Meier Friedegund, Diem Stefan, Cozzio Antonio, Flatz Lukas, Röcken Martin, Garbe Claus, Gassenmaier Maximilian, Weide Benjamin, Leiter Ulrike, Lenders Max M, Kühl Kathrin, Reinhardt Lydia, André Fiona, Dudda Milena, Ring Natalie, Ebel Chiara, Stäger Ramon, Zellweger Caroline, Lang Roland, Paar Michael, Gussek Philipp, Richtig Georg, Stürmer Suzan H, Kimeswenger Susanne, Oellinger Angela, Forschner Andrea, Eigentler Thomas K
Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy
Bochem J, Meier F, Terheyden P, Königsrainer A, Garbe C, Flatz L, Pawelec G, Eigentler T, Löffler M, Weide B, Niessner H, Sinnberg T, Zelba H, Spreuer J, Amaral T, Gaissler A, Pop O, Thiel K, Yurttas C, Soffel D, Forchhammer S, Wistuba-Hamprecht K. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy. J Immunother Cancer 2021; 9
Jan 1, 2021Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy
Jan 1, 2021J Immunother Cancer 2021; 9
Bochem Jonas, Meier Friedegund, Terheyden Patrick, Königsrainer Alfred, Garbe Claus, Flatz Lukas, Pawelec Graham, Eigentler Thomas K, Löffler Markus W, Weide Benjamin, Niessner Heike, Sinnberg Tobias, Zelba Henning, Spreuer Janine, Amaral Teresa, Gaissler Andrea, Pop Oltin, Thiel Karolin, Yurttas Can, Soffel Daniel, Forchhammer Stephan, Wistuba-Hamprecht Kilian
Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade
Bochem J, Weide B, Pawelec G, Garbe C, Meier F, Terheyden P, Uslu U, Wagner N, Eigentler T, Soffel D, Spreuer J, Amaral T, Zelba H, Wistuba-Hamprecht K. Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade. PloS one 2019; 14:e0221301.
Aug 16, 2019Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade
Aug 16, 2019PloS one 2019; 14:e0221301
Bochem Jonas, Weide Benjamin, Pawelec Graham, Garbe Claus, Meier Friedegund, Terheyden Patrick, Uslu Ugur, Wagner Nikolaus, Eigentler Thomas, Soffel Daniel, Spreuer Janine, Amaral Teresa, Zelba Henning, Wistuba-Hamprecht Kilian
Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients
Meier F, Garbe C, Knaudt B, Zielinski C, Leiter U, Forschner A, Eigentler T, Clasen S, Guenova E, Berneburg M. Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients. J Am Acad Dermatol 2009; 60:863-8.
May 1, 2009Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients
May 1, 2009J Am Acad Dermatol 2009; 60:863-8
Meier Friedegund, Garbe Claus, Knaudt Björn, Zielinski Christina, Leiter Ulrike, Forschner Andrea, Eigentler Thomas, Clasen Stephan, Guenova Emmanuella, Berneburg Mark